Annet Kirabo, D.V.M., Ph.D., FAHA, professor of medicine at Vanderbilt Health, will receive the 2026 Joseph A. Vita Award from the American Heart Association at its Scientific Sessions in Chicago, Nov. 6-9, 2026. The award, presented during the Opening Session on Nov. 7, recognizes a scientist whose research has significantly advanced cardiovascular biology or health within the past five years and whose work has been published in the Association's journals. Dr. Kirabo's selection matters because her discoveries have fundamentally changed how scientists understand hypertension, revealing that immune activation and inflammation are not merely consequences but drivers of high blood pressure. This paradigm shift opens new avenues for preventing and treating hypertension and related cardiovascular and kidney diseases.
Named after the late Joseph A. Vita, M.D., founding editor of the Journal of the American Heart Association (JAHA), the award celebrates research that transforms or changes the direction of cardiovascular science. Dr. Kirabo's work identified lipid oxidation-derived protein adducts as neoantigens that trigger antigen-presenting cell activation, T-cell responses, vascular dysfunction and hypertension. This discovery provided a mechanistic link between the immune system and blood pressure regulation, a connection that had been largely overlooked. Her laboratory now integrates immunology, vascular biology, genomics, metabolomics and single-cell technologies to identify new therapeutic targets, including reactive lipid molecules called isolevuglandins and sodium-sensing pathways in immune cells.
"Dr. Annet Kirabo exemplifies the spirit of the Joseph A. Vita Award, which recognizes research that changes the direction of cardiovascular science," said Manesh R. Patel, M.D., FAHA, the American Heart Association's 2026-2027 volunteer president. "Her pioneering discoveries represent a paradigm shift in cardiovascular biology, reshaping our understanding of hypertension by revealing how immune activation and inflammation drive cardiovascular disease." The implications are profound: if immune activation drives hypertension, then immunomodulatory therapies could become new tools for blood pressure control, potentially benefiting millions who struggle with resistant hypertension.
Dr. Kirabo has been an active Heart Association volunteer since 2009, serving on the Council on Hypertension Communications Committee, including as chair from 2022 to 2024, and on the Council Operations Committee since 2024. She has served on the editorial board of the Hypertension journal since 2018 and as an associate editor of Circulation Research since 2019. Her extensive publication record of more than 230 scientific papers and sustained NIH funding underscore her influence. Beyond research, she mentors dozens of graduate students and postdoctoral fellows, many of whom have become independent investigators, thereby shaping the future of cardiovascular science.
"I am deeply honored to receive the Joseph A. Vita Award from the American Heart Association, an organization that has supported my career from my predoctoral and postdoctoral fellowships through my development as an independent investigator," said Dr. Kirabo. "Scientific discovery, mentorship and advancing new treatments for cardiovascular disease have been the primary focus of my career, and it is both rewarding and humbling to be recognized for it." Her journey from Makerere University in Uganda to Vanderbilt University highlights the global impact of her work. Additional resources, including multimedia, are available on the right column of the release link. For more information about the American Heart Association, visit heart.org or stroke.org.
